Access to healthcare, and particularly radiotherapy, is at the core of Elekta's business. We aim to improve access to healthcare globally, especially in low- and middle-income countries. This matters since cancer is the second leading cause of death globally. In 2020, it accounted for an estimated 10 million deaths, or one of six, globally. Half of all cancer patients require radiotherapy as part of their care, yet 70 percent of all radiotherapy equipment globally is available to only 25 percent of the world's population.
Elekta has a unique opportunity to fight cancer and alleviate the suffering of people affected by cancer in all corners of the world. The incidence of cancer is rising globally and there is a pressing need for radiotherapy services. Everyone deserves high-quality care, but it is not always available. Elekta is committed to improving access to radiotherapy for all, not least in currently underserved markets. The world community has set an ambitious target, as part of Agenda 2030, of reducing mortality from non-communicable diseases, such as cancer, by one third by 2030. Increasing access to radiotherapy will be crucial in reaching this target. Equitable access to medical care is a fundamental human right, and one we are committed to stand up for.
Not only are we contributing to this through our direct business purpose and our innovative and high-quality solutions to improve access. Also through our efforts in increasing education and training (with special focus on low- and middle income countries, see e.g. BrachyAcademy) and through our agenda for raising global awareness with carefully selected international organizations (e.g. City Cancer Challenge and Union for International Cancer Control).
Our target is to increase installed linear accelerators in low- and middle-income countries so that 300 million additional people in these countries will get access to radiotherapy by 2024/25. This is equivalent to an additional 400,000 actual cancer treatments by 2024/25.